Abstract
Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.
| Original language | English |
|---|---|
| Pages (from-to) | 234-243 |
| Number of pages | 10 |
| Journal | Nature Reviews Nephrology |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Novel approaches for reducing free light chains in patients with myeloma kidney. / Hutchison, Colin A.; Bladé, Joan; Cockwell, Paul; Cook, Mark; Drayson, Mark; Fermand, Jean Paul; Kastritis, Efstathios; Kyle, Robert; Leung, Nelson; Pasquali, Sonia; Winearls, Christopher.
In: Nature Reviews Nephrology, Vol. 8, No. 4, 04.2012, p. 234-243.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel approaches for reducing free light chains in patients with myeloma kidney
AU - Hutchison, Colin A.
AU - Bladé, Joan
AU - Cockwell, Paul
AU - Cook, Mark
AU - Drayson, Mark
AU - Fermand, Jean Paul
AU - Kastritis, Efstathios
AU - Kyle, Robert
AU - Leung, Nelson
AU - Pasquali, Sonia
AU - Winearls, Christopher
PY - 2012/4
Y1 - 2012/4
N2 - Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.
AB - Myeloma kidney is a tubulointerstitial pathology that accounts for approximately 80-90% of severe acute kidney injury in patients with multiple myeloma. Unless there is rapid intervention, progressive irreversible damage from interstitial fibrosis and tubular atrophy occurs. Work over the past decade has demonstrated that an early sustained reduction in serum concentrations of pathogenic monoclonal free light chains (FLCs) leads to improved renal recovery rates. In turn, an early improvement in renal function is associated with improved patient survival. An early reduction in FLC levels should therefore become standard of care, although the optimum mechanisms to achieve this depletion of FLCs remain to be determined. To provide a coordinated, cross-disciplinary approach to research in this disease, the International Kidney and Monoclonal Gammopathy Research Group was formed. In this Review, we address the current state of knowledge in the management of myeloma kidney.
UR - http://www.scopus.com/inward/record.url?scp=84859002570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859002570&partnerID=8YFLogxK
U2 - 10.1038/nrneph.2012.14
DO - 10.1038/nrneph.2012.14
M3 - Article
C2 - 22349488
AN - SCOPUS:84859002570
VL - 8
SP - 234
EP - 243
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
SN - 1759-507X
IS - 4
ER -